share_log

EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target

Benzinga ·  07/11/2023 00:15

EF Hutton analyst Elemer Piros reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $2 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment